TrumpRx/MFN pricing risks could pressure margins despite 9.3x fwd P/E, 6.27% dividend and pipeline gains. Read the latest ...

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Pfizer Inc. (NYSE:PFE) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 24, Guggenheim Partners raised its price recommendation on Pfizer Inc. (NYSE:PFE) to ...

Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks under $50 to invest in now. Pfizer Inc. (NYSE:PFE) announced on ...

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we ...

Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer. The move, announced Thursday, escalates the competition between the two ...

PFE stock is up 11% in 2026, but flat guidance, falling COVID sales and patent cliffs cloud its rebound story. Buy, sell or ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated a Buy rating on Pfizer Inc. (NYSE:PFE) on December 17 and set a price ...

Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion. PFE is ...

From a price-performance perspective, PFE has fetched better returns than BMY so far this year. Shares of PFE have risen 2%, ...